Objectives-This study reviewed the literature to directly evaluate the diagnostic performance of contrast-enhanced ultrasonography (CEUS) versus contrastenhanced computed tomography (CECT) for assessing residual tumors of hepatocellular carcinoma treated with transarterial chemoembolization.
M alignant tumors, including hepatocellular carcinoma (HCC), are responsible for approximately 600,000 to 700,000 deaths per year and are becoming more prevalent worldwide. 1 For the treatment of unresectable HCC, transarterial chemoembolization (TACE) with an emulsion of iodized oil has been widely used. 2, 3 The therapeutic response of TACE can be assessed by traditional contrast-enhanced computed tomography (CECT). However, recent studies have suggested that it is not as accurate as previously thought for evaluating the response 4, 5 ; high signals due to accumulated lipiodol may mask the enhancement of HCC, making it difficult to identify the residual tumor correctly by CECT. 6 Furthermore, tumor regression is rarely observed immediately after TACE, 7 as dense iodized oil accumulation can be observed in both HCC and normal hepatic tissue within 4 weeks after chemoembolization. 8 Therefore, evaluation of residual tumors using CECT typically must be delayed by 1 month after TACE. 9 To obtain a better survival rate, additional treatments after TACE need to be determined as early as possible, such as repeated TACE or sorafenib interventions. 10, 11 Contrast-enhanced ultrasonography (CEUS) has been recently applied to evaluate the therapeutic response shortly after TACE. 12 Compared with CECT, CEUS is less affected by lipiodol retention and is more sensitive to detecting residual enhancement. 13 Minami et al 14 found that CEUS was highly sensitive and accurate for evaluating treatment responses, even shortly (1 week) after TACE. Furthermore, nodules that were fully filled with lipiodol could also be detected as incomplete responses by CEUS.
Thus, it is essential to determine the diagnostic value of CEUS versus CECT for assessing treatment responses after TACE. Thus far, several single-center studies concerning the diagnostic accuracy of CEUS versus CECT for the assessment of treatment responses after TACE have been published. 6, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] However, no multicenter large-sample study has been published to date. Therefore, this meta-analysis aimed to summarize previously reported findings to provide insight into the diagnostic accuracy of CEUS versus CECT for assessing residual tumors of HCCs treated with TACE.
Materials and Methods

Search Strategy
PubMed, Embase, the Cochrane Library, and the China National Knowledge Infrastructure were searched for articles published up to April 30, 2017 . The following search terms were used: (1) hepatocellular carcinoma, hepatic carcinoma, liver cell carcinoma, liver cancer, hepatoma, and HCC; (2) therapeutic chemoembolization, transarterial chemoembolization, transhepatic arterial chemotherapy and embolization, and TACE; and (3) contrast-enhanced ultrasonography, contrast enhanced ultrasound, ultrasound contrast imaging, and CEUS.
Study Inclusion and Exclusion
Studies were included if they met all of the following inclusion criteria: (1) both CECT and CEUS were performed in participants, and the diagnostic performances were compared directly; (2) patients received TACE alone during the study period (ie, not combined with other treatments); and (3) either the absolute number of true-positive, false-positive, false-negative, and truenegative results or the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) could be gathered or calculated from the full text, as previously described in detail. 23 The studies were extracted independently by 2 investigators (J.Z. and P.L.). If there was a discrepancy between the investigators, disagreements were resolved by consultation with a third investigator (Z.S.). Studies were excluded on the basis of the following criteria: (1) the publication included case reports, reviews, or comments; (2) the publication did not report diagnostic performance about the identified outcome of interest; and (3) there was possible overlap of samples.
Study Selection and Data Extraction
Articles were reviewed independently by 2 investigators for inclusion and exclusion. The data of interest were extracted by using a predefined form. Any disagreements in study selection or data extraction were resolved by consensus. The following data for eligible studies were extracted: (1) characteristics of the studies-author, publication date, country, and study design; (2) study quality-the quality of the included studies was assessed by the Quality Assessment of Diagnostic Accuracy Studies 24 ; 2 investigators (J.Z. and Y.Z.) independently performed a quality assessment of the included studies, and disagreements were resolved by discussion; (3) characteristics of the patients-number of patients, mean age, sex, number of nodules, mean diameter of tumors, emulsion of TACE, reference standard for residual tumors, first time of CEUS and CECT after TACE, contrast agents, and parameters of examinations; and (4) true-positive, false-positive, false-negative, and true-negative results gathered or calculated from each study.
Data Synthesis and Statistical Analysis
Data synthesis and statistical analysis were performed with Meta-DiSc version 1.4 (Ram on y Cajal Hospital, Madrid, Spain) and Stata 12.0 (StataCorp, College Station, TX) software. A funnel plot and Begg test were used to evaluate the potential publication bias. P < .05 indicate that there was a publication bias. Potential heterogeneity, indicating variations between studies, was evaluated by calculating the I 2 statistic. An I 2 of greater than 50% suggested that there was significant heterogeneity. Data with heterogeneity were pooled by a random-effects model (DerSimoniane-Laird model), whereas data without heterogeneity were pooled by a fixed-effects model (Mantel-Haenszel model), as previously described in detail. 23 The main analysis was focused on the pooled diagnostic accuracy of CEUS versus CECT. The pooled sensitivity, specificity, positive likelihood ratio (LR), negative LR, PPV, NPV, and diagnostic odds ratio (OR) were calculated by using suitable models determined by the heterogeneity evaluation and were provided with 95% confidence intervals (CIs) calculated via an F distribution, as previously described in detail. 23 Diagnostic threshold variations among publications were evaluated by calculating the Spearman correlation coefficient and a summary receiver operating characteristic (ROC) curve.
The area under the curve (AUC) was explored. In a summary ROC curve, the Q* point is the point where the curve is intersected by a diagonal running from the top left to the bottom right corner of the ROC space and provides an estimate of composite sensitivity and specificity. 25 Statistical differences of pooled sensitivity, specificity, PPV, and NPV between CEUS and CECT were determined by the v 2 test, whereas differences in the AUC were compared by the U test. P < .05 was considered statistically significant.
Results
Literature Search
A total of 807 studies were identified by the search strategy. After exclusion based on the title, abstract, or text, a total of 11 studies were included in the meta-analysis. A flow diagram of the review process and the reasons for exclusion are presented in Figure 1 .
Characteristics of the Included Studies
The included studies were published between 2003 and 2017 and included 10 prospective studies and 1 retrospective study. A total of 421 patients and 491 nodules were analyzed, with a mean age ranging from 45 to 70 years and a mean tumor diameter ranging from 25 to 49 mm. More male than female patients were examined. digital subtraction angiography and pathologic analysis were the major reference standards in all studies. However, CECT after 2 to 6 months and magnetic resonance imaging after 1 to 3 months were also acceptable in 3 studies. The main characteristics of the studies are summarized in Tables 1 and 2 . The overall quality of the included studies was good; all of the studies had a "yes" rating for more than 10 of 14 items (Table 3) . Figure 2 ). Figure 3 and Table 4 ).
Diagnostic Accuracy of CEUS and CECT
For CECT, the pooled sensitivity and specificity were 0.72 (95% CI, 0.67-0.76) and 0.99 (95% CI, 0.95-1.00), respectively. The pooled PPV was 1.00 (95% CI, 0.98-1.00), whereas the pooled NPV was 0.51 (95% CI, 0.44-0.58). The pooled positive and negative LR were 12.50 (95% CI, 5.74-27.20) and 0.35 (95% CI, 0.26-to 0.48). The summary diagnostic OR was 35.54 (95% CI, 14.89-84.83; Figure 4 and Table 4 ). The sensitivity and NPV of CEUS were significantly higher than those of CECT (both P < .001), whereas the specificity and PPV of CECT were significantly higher than those of CEUS (both P < .05; Table 4 ).
Diagnostic Threshold Effect
Spearman correlation coefficients were -0.138 (P 5 .686) for CEUS and -0.189 (P 5 .579) for CECT, indicating that no diagnostic threshold effect existed among studies. Symmetric summary ROC curves were drawn ( Figure 5 ). The AUCs were 0.9875 for CEUS (Q* 5 0.9525) and 0.9239 for CECT (Q* 5 0.8579). There was no significant difference between the AUCs of CEUS and CECT (P 5 .13).
Discussion
To the best of our knowledge, several single-center studies 6,13-22 and a systematic review 26 concerning the diagnostic accuracy of CEUS versus CECT for assessing the treatment response after TACE have been published. However, the single-center studies generally included small sample sizes and reported varying results when comparing CEUS with CECT. In addition, there was no specification of data synthesis in the systematic review. 26 Furthermore, the populations were not composed of individual patients with HCC who underwent only TACE in the systematic review but rather included patients who underwent other nonsurgical therapies, such as radiofrequency ablation, percutaneous ethanol injection, and TACE combined with other treatments. Total Y  12  13  11  12  12  11  11  12  11  13  14 N indicates no; Y, yes; and Uc, unclear.
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These variations made comparisons of the 16 studies in the systematic review difficult and a meta-analysis impossible. Therefore, to our knowledge, this study is the first meta-analysis that directly compared CEUS and CECT for evaluating the treatment response of patients with HCC who underwent TACE alone. According to the results, both CEUS and CECT had high overall diagnostic accuracy (AUCs, 0.9875 and 0.9239; P 5 .13). However, CEUS had a better sensitivity, NPV, and negative LR versus CECT; CECT had a higher specificity and positive LR versus CEUS. Therefore, CEUS is an effective method for the exclusion of residual tumors after TACE, and CECT is a valid approach to identify residual tumors. However, CEUS cannot replace CECT in the follow-up of treated nodules because it does not always clearly depict the border between the tumor and the surrounding liver parenchyma. 27 According to current evidence, [13] [14] [15] [16] [17] 19, [21] [22] [23] CEUS is more sensitive than CECT in detecting residual tumors, revealing changes after repeated TACE treatments or other interventions at the early stage of recurrence, even within 1 month after TACE. This capability may be of particular value when assessment via CECT is restricted, as iodized oil retention may obscure the enhanced area within the tumor. 28 It usually takes at least 3 to 4 weeks for iodized oil to be washed out from the surrounding liver parenchyma after TACE. 29 Additionally, a radiation hazard and renal iodine contrast toxicity often limit repeated applications of CECT in patients with HCC. In contrast, CEUS is a radiation-free, well-tolerated, inexpensive, real-time method. Furthermore, the high NPV of CEUS can imply complete tumor necrosis if there is no enhancement in the arterial phase, and the low negative LR of CEUS demarcates patients without residual tumors, thus preventing unnecessary examinations. However, the specificity of CECT approached nearly 100% (versus 90% for CEUS; P 5 .001), suggesting that the misdiagnosis rate for CECT was much lower than that for CEUS in detecting residual tumors. The PPV and positive LR of CECT were as high as 100% and 12.50, respectively, indicating that CECT is highly useful for definitively diagnosing an incomplete response and The results indicated pooled sensitivity of 97% (95% CI, 95%-99%) and specificity of 90% (95% CI, 83%-95%). The range of statistics related to diagnostic accuracy was relatively wide in some studies.
can raise the posttest probability of a patient who is suspected to have residual tumors.
Various heterogeneities existed among the individual studies included in this meta-analysis because of clinical and methodological diversity. A retrospective study was included in this review, thus possibly introducing confounding, selection, and information biases. In addition, the reference standard, CT parameters, contrast agents, and time of evaluation after TACE also varied among the studies. For CEUS, the pooled specificity (I 2 5 51.0%) was significantly heterogeneous. The specificity in many studies was as high as 100%, whereas it was only 65% and 83% in publications by Kim et al 6 and Takizawa et al, 17 respectively. The relatively low specificity might result from several limitations of CEUS. False-positive results may be due to artifactual signals within the tumor associated with microbubbles, and false-negative results may occur when the HCC lesion is undetectable by CEUS because of obscure margins or a distance of greater than 12 cm from the skin surface. 17, 26 In addition, the first-generation air-based contrast agent Levovist (Schering AG, Berlin, Germany) was used in the study by Kim et al, 6 which could not produce realtime images and required a higher mechanical index that destroys the microbubbles and results in image artifacts 30 compared with the second-generation sulfur hexafluoride microbubble-based contrast agent SonoVue (Bracco SpA, Milan, Italy). These factors may have contributed to the relatively low specificities of CEUS in their studies. For CECT, the pooled sensitivity (I 2 5 72.0%) was moderately heterogeneous. As discussed above, high signals caused by accumulated lipiodol (which may mask the enhancement of residual tumors) make it difficult to evaluate treatment responses and represent the most important disadvantage that affects CECT. Differentiation between a small viable tumor and hyperattenuating lipiodol becomes difficult, and the tiny viable tumor, if present, maybe masked by The results indicated pooled sensitivity of 72% (95% CI, 67%-76%) and specificity of 99% (95% CI, 95%-100%). The range of statistics related to diagnostic accuracy was relatively wide in some studies. Figure 5 . Summary ROC (SROC) curves for CEUS (A) and CECT (B). The AUC for CEUS was higher than that for CECT; however, there was no significant difference between the AUCs for CEUS and CECT (P >.05).
lipiodol, which appears similar on imaging. 31 In addition, in previous studies, 32, 33 it was reported that there was still a high tumor survival rate in the lipiodol deposition area of CT. Minimal lipiodol-deficient areas in lesions with good lipiodol deposition may be missed because of the partial volume effect of CT. Studies published by Minami et al, 14 Chen et al, 15 and Cho et al 19 had particularly low sensitivities (47%, 45%, and 38%, respectively), partly because of the small numbers of participants in these studies, which might have led to an inaccurate statistical analysis.
The evidence considered in this review corresponded to several limitations. (1) The small number of studies and total number of patients may have affected the outcomes and were the main limitations of this present meta-analysis. Heterogeneities existed among studies, and we could not perform a subgroup or metaregression analysis to fully explore the sources of heterogeneity to make a definitive conclusion because of the limited number of studies. A further meta-analysis is necessary after more relevant studies are published. (2) A retrospective study was included in this review, which introduced potential selection and confounding biases. (3) The first-generation air-based contrast agent Levovist has several limitations. It cannot produce real-time images and requires a high mechanical index that destroys the microbubbles and results in image artifacts. These limitations may have influenced the accuracy of assessing residual tumors.
In conclusion, this meta-analysis indicates that CEUS is a viable alternative for residual tumor exclusion after TACE, especially during early stages (within a month). In addition, it may provide a sensitivity and negative LR to comparable with those of CECT. However, it is unlikely for CEUS to replace CECT, as CECT is a valid approach for identifying residual tumors. However, large prospective multicenter studies with a proper design are needed to confirm these findings.
